Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures.
Peindl M, Göttlich C, Crouch S, Hoff N, Lüttgens T, Schmitt F, Pereira JGN, May C, Schliermann A, Kronenthaler C, Cheufou D, Reu-Hofer S, Rosenwald A, Weigl E, Walles T, Schüler J, Dandekar T, Nietzer S, Dandekar G. Peindl M, et al. Among authors: schuler j. Cancers (Basel). 2022 Apr 27;14(9):2176. doi: 10.3390/cancers14092176. Cancers (Basel). 2022. PMID: 35565305 Free PMC article.
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.
Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. Wellner U, et al. Among authors: schuler j. Nat Cell Biol. 2009 Dec;11(12):1487-95. doi: 10.1038/ncb1998. Epub 2009 Nov 22. Nat Cell Biol. 2009. PMID: 19935649
Targeting mitotic exit in solid tumors.
Greil C, Felthaus J, Follo M, Ihorst G, Ewerth D, Schüler J, Schnerch D, Duyster J, Engelhardt M, Wäsch R. Greil C, et al. Among authors: schuler j. Am J Cancer Res. 2021 Jul 15;11(7):3698-3710. eCollection 2021. Am J Cancer Res. 2021. PMID: 34354869 Free PMC article.
PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer.
Talwelkar SS, Mäyränpää MI, Schüler J, Linnavirta N, Hemmes A, Adinolfi S, Kankainen M, Sommergruber W, Levonen AL, Räsänen J, Knuuttila A, Verschuren EW, Wennerberg K. Talwelkar SS, et al. Among authors: schuler j. Mol Oncol. 2023 May;17(5):747-764. doi: 10.1002/1878-0261.13342. Epub 2023 Jan 25. Mol Oncol. 2023. PMID: 36423211 Free PMC article.
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.
Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, Puhr M, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T. Meidhof S, et al. Among authors: schuler j. EMBO Mol Med. 2015 Jun;7(6):831-47. doi: 10.15252/emmm.201404396. EMBO Mol Med. 2015. PMID: 25872941 Free PMC article.
311 results